Coya Therapeutics Secures $11.1M Private Placement, Receives FDA Fast Track for ALS Drug

summarizeSummary

Coya Therapeutics announced its Q1 2026 results, revealing an $11.1 million private placement and FDA Fast Track Designation for its ALS drug candidate, COYA 302, enhancing its financial position and clinical development path.

check_boxKey Events

• Successful Capital Raise

  The company completed an $11.1 million private placement in January 2026 by selling 2,522,727 shares of common stock at $4.40 per share, significantly boosting its cash reserves.

• FDA Fast Track Designation Granted

  COYA 302, the company's lead asset for Amyotrophic Lateral Sclerosis (ALS), received Fast Track Designation from the FDA on May 11, 2026, which could expedite its clinical development and regulatory review.

• Extended Cash Runway

  As of March 31, 2026, cash and cash equivalents stood at $50.7 million, expected to fund operating expenses and capital requirements for at least one year from the filing date, consistent with prior guidance.

• Q1 2026 Financial Performance

  The company reported a net loss of $7.2 million for Q1 2026, a slight improvement from $7.3 million in Q1 2025. Research and development expenses decreased to $4.1 million, while general and administrative expenses increased to $3.8 million, partly due to a $1.0 million non-cash charge related to a former Executive Chairman's option modification.

auto_awesomeAnalysis

Coya Therapeutics reported its first-quarter 2026 financial results, highlighting a successful $11.1 million private placement completed in January 2026. This capital infusion significantly bolsters the company's liquidity, extending its cash runway for at least one year from the filing date. Additionally, the company announced that its lead asset, COYA 302 for ALS, received FDA Fast Track Designation on May 11, 2026, a critical regulatory milestone that could accelerate its development and review process. These positive developments are crucial for a clinical-stage biotechnology company, providing financial stability and regulatory momentum for its key therapeutic candidate.